Protego Biopharma Inc. closed an oversubscribed $130 million series B financing that will be used to advance PROT-001, the company’s treatment for amyloid light (AL) chain amyloidosis. a plasma cell disorder where the cells produce abnormal, misfolded immunoglobulin light chain proteins.

Biopharmas raising money in public or private financings, including: Faron, Nuvalent, Pharmacyte, Tempest, Zetagen.

Biopharmas raising money in public or private financings, including: Azitra, Enlivex, Fibrobiologics, Mindimmune, Scilex, Vaxil, Verrica.

Biopharmas raising money in public or private financings, including: Bioatla, Inhibikase.

Biopharmas raising money in public or private financings, including: Biovaxys, Cassidy, Moderna.

Biopharmas raising money in public or private financings, including: AI Proteins, Fibrobiologics, Genmab, HCW, Hemostemix, Lifordi, Mendus, Nervgen, Nuvalent, Olema, Seragene, Skeletalis.

Biopharmas raising money in public or private financings, including: Angiex, Avanzanite, Bambusa, Fennec, Invivyd, Respirerx, Solve.

Biopharmas raising money in public or private financings, including: Algernon, Annexon, Artios, Bambusa, Captain T Cell, Imbria, Inventiva, Mitorx, Nextcure.